Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.50
Bid: 1,604.00
Ask: 1,604.50
Change: 4.50 (0.28%)
Spread: 0.50 (0.031%)
Open: 1,600.50
High: 1,612.50
Low: 1,591.00
Prev. Close: 1,595.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FTSE 100 slips as ex-dividend trades weigh, Rolls-Royce soars

Thu, 23rd Feb 2023 17:10

Rolls-Royce jumps on upbeat forecast

*

Major banks and healthcare stocks trade ex-div

*

FTSE 100 down 0.3%, FTSE 250 adds 0.6%

Feb 23 (Reuters) - The FTSE 100 ended lower on Thursday, as several banking and healthcare heavyweights traded ex-dividend, although shares of Rolls-Royce zoomed more than 20% after the aeroplane engine maker reported upbeat results.

The blue-chip index was down 0.3%, declining for a third straight session.

Shares of banks including Barclays and Standard Chartered and healthcare majors AstraZeneca and GSK slipped as they traded without entitlement for dividend payout.

Limiting losses on the FTSE 100 however Rolls-Royce surged 23.7% to post its biggest percentage gain in more than two years after the company's CEO forecast more profit growth in 2023.

"There was a lot of concern coming into this year generally about margins, results and (if) companies would be able to maintain their margins," said Caroline Simmons, UK chief investment officer at UBS Global Wealth Management.

"But what we've been seeing is so far the results have been broadly okay."

The FTSE 250 midcap index rose 0.6%, with John Wood Group Plc jumping 29.0% to the top of the index after the oilfield services and engineering firm said it received and rejected takeover proposals from Apollo Global Management.

Meanwhile, Bank of England interest rate-setter Catherine Mann said that it was

too soon to say

the risks posed by the surge in inflation last year had eased and that the central bank should continue to raise borrowing costs.

"Right now, the main driver for equities is just this reassessment of whether we have in fact priced peak rates, even if it means the recession is not coming," said Michael Metcalfe, head of macro strategy at State Street Global Markets.

Strong economic data in January has shaken investor confidence, he added.

Among other single stocks, Mondi fell 4.8% after the paper packaging company gave a cautious outlook.

Drax Group lost 3.7% as analysts said falling forward sales could hit the power generation firm's core earnings in 2024. The company posted annual profit that beat analysts' expectation. (Reporting by Shashwat Chauhan and Shristi Achar A in Bengaluru; editing by Uttaresh.V, Eileen Soreng and Andrew Heavens)

More News
2 Aug 2023 14:28

GSK sues Pfizer in US for patent infringement over RSV vaccine

Aug 2 (Reuters) - British biopharmaceutical giant GSK sued Pfizer in Delaware federal court on Wednesday, accusing Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo of violating GSK's patent rights in its rival RSV shot Arexvy.

Read more
2 Aug 2023 10:41

Sensodyne maker Haleon's shiny forecast signals price hikes unlikely to dent demand

Shares down 1% on slight decline in H1 adj operating margin

*

Read more
2 Aug 2023 08:23

TOP NEWS: Haleon boosts annual guidance after solid first half

(Alliance News) - Haleon PLC on Wednesday upped its annual organic revenue growth guidance following a solid revenue performance in the first half of 2023.

Read more
31 Jul 2023 19:42

IN BRIEF: GSK hails US FDA approval for cancer treatment, Jemperli

GSK PLC - London-based pharmaceutical company - Jemperli plus chemotherapy approved in the US by the Food & Drug Administration as the first new frontline treatment option in decades for primary advanced or recurrent endometrial cancer. Notes Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy. Hesham Abdullah, senior vice president and global head of oncology development at GSK, says: "Today's approval underscore our belief in the potential for Jemperli to transform cancer treatment as a backbone immuno-oncology therapy."

Read more
31 Jul 2023 12:21

DIRECTOR DEALINGS: Qinetiq, Tesco and GSK executives sell shares

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced late last week and not separately reported by Alliance News:

Read more
31 Jul 2023 09:16

LONDON BROKER RATINGS: Oddo BHF raises IAG to 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
26 Jul 2023 11:06

GSK raises 2023 outlook boosted by vaccine, HIV drug sales

Q2 sales and earnings beat estimates

*

Read more
26 Jul 2023 09:28

TOP NEWS: GSK raises annual guidance on quarterly earnings growth

(Alliance News) - GSK PLC on Wednesday upgraded its full-year guidance, after seeing a strong quarterly performance on the strength of segments like HIV and Vaccines.

Read more
26 Jul 2023 07:55

GSK lifts full-year guidance after 'excellent' Q2

(Sharecast News) - GSK lifted its full-year guidance on Wednesday after an "excellent" second quarter.

Read more
24 Jul 2023 08:25

GSK says HIV prevention drug recommended for marketing in Europe

(Alliance News) - GSK PLC on Monday said ViiV Healthcare's cabotegravir for HIV prevention has received a positive opinion by the European Medicines Agency for marketing authorisation.

Read more
24 Jul 2023 07:07

GSK's ViiV gets Europe nod for HIV prophylaxis

(Sharecast News) - Pharmaceuticals giant GSK announced on Monday that its majority-owned HIV specialist subsidiary ViiV Healthcare has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending marketing authorisation for 'cabotegravir' long-acting (LA) injectable and tablets for HIV prevention.

Read more
22 Jul 2023 18:32

Bavarian Nordic ends RSV vaccine programme after poor trial results

July 22 (Reuters) - Denmark-based Bavarian Nordic said on Saturday it was ending its respiratory syncytial virus (RSV) vaccine programme as its Phase 3 clinical trial did not meet all the primary goals of preventing lower respiratory tract disease.

Read more
14 Jul 2023 09:13

LONDON BROKER RATINGS: HSBC says 'buy' AstraZeneca but 'reduce' GSK

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
14 Jul 2023 07:56

LONDON BRIEFING: Burberry shines in China; ITV-All3Media deal unlikely

(Alliance News) - Stocks in London are expected to slip into the red at Friday's open, in a tepid conclusion to what has been a largely positive week for global equities, as the market prices in a lower peak for US interest rates.

Read more
13 Jul 2023 16:13

Sensodyne toothpaste-maker Haleon planning job cuts - The Guardian

July 13 (Reuters) - Haleon, the world's biggest standalone consumer health business, is planning to cut hundreds of roles in the UK and worldwide, the Guardian reported on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.